Signed a joint research agreement with Yokohama City University, a public university corporation. Conducting efficacy evaluation of HGF for CIPN. Describes only a minor impact on business performance from R&D expenses.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"CrinklePharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4884-20260904-01.pdf","jir_short_summary":"Signed a joint research agreement with Yokohama City University, a public university corporation. Conducting efficacy evaluation of HGF for CIPN. Describes only a minor impact on business performance from R&D expenses.","jir_summary":"### Section Heading\nThis is a notification regarding the conclusion of a joint research agreement with Yokohama City University, a public university corporation. We will jointly conduct efficacy evaluation tests of HGF for CIPN (chemotherapy-induced peripheral neuropathy). The research will be conducted with lecturer Takuya Sato of the Graduate School of Life Nano System Science at Yokohama City University, and if the efficacy of HGF is demonstrated, it is expected to create new treatment strategies. It is noted that the impact on our performance is expected to be minor relative to R&D expenses.\n\n### Section 2 Heading\nAs background, CIPN is a representative side effect of anticancer drug therapy, and there are currently no established effective prevention or treatment methods. HGF has multiple biological activities such as neuroprotection and axonal growth, and is\u671f\u5f85\u3055\u308c\u3066\u3044\u308b as a therapeutic for neurodegenerative diseases. Depending on future research results, market opportunities may expand.","jir_financial_highlights":"Impact of R&D expenses on performance: Unknown (Minor)","jir_category":"","jir_hashtags":"#ourR&D, #jointResearch, #neurodegenerativeDiseaseTherapy","jir_key_figures":"Impact of R&D expenses on performance: Minor\nDate of conclusion of joint research agreement: Unknown\nCounterparty: Yokohama City University","jir_meta_title":"\u3010CrinklePharma\u3011Conclusion of joint research agreement with Yokohama City University | Initiation of HGF efficacy evaluation for CIPN","jir_meta_description":"CrinklePharma concludes a joint research agreement with Yokohama City University. Joint evaluation of the efficacy of HGF for CIPN. Minor impact on R&D expenses. Expectation for future treatment strategy development.","jir_og_title":"\u3010CrinklePharma\u3011Announcement of Joint Research with Yokohama City University","jir_og_description":"CrinklePharma begins joint research with Yokohama City University to evaluate the efficacy of HGF for CIPN. Stated minor impact on performance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-110740","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n